Sou Hu Cai Jing·2025-12-09 03:13Core Insights - The National Healthcare Security Administration (NHSA) has released the updated National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog, adding 114 new drugs, significantly enhancing coverage in key areas such as oncology [1][2] - The report highlights a successful establishment of a clear direction for supporting genuine and differentiated innovation through strategic purchasing [1] - The commercial health insurance drug catalog has been introduced, complementing the basic medical insurance and laying the foundation for a multi-tiered medical security system [3] Group 1: Drug Catalog Adjustments - The recent adjustment added 114 new drugs, including 50 class 1 innovative drugs, with an overall negotiation success rate of 88%, up from 76% in 2024 [2] - The total number of drugs in the catalog has increased to 3,253, with significant improvements in coverage for oncology, chronic diseases, mental illnesses, rare diseases, and pediatric medications [2] Group 2: Financial Implications - During the 14th Five-Year Plan period, the cumulative expenditure of the medical insurance fund exceeded 13 trillion yuan, benefiting nearly 20 billion patient visits [1] - Over the past seven years, 835 new drugs have been included in the medical insurance payment scope, with 149 of them being innovative drugs, and approximately 80% of innovative drugs being included within two years of market launch [1] Group 3: Commercial Health Insurance Developments - The first version of the commercial health insurance innovative drug catalog includes 19 drugs, focusing on high innovation, significant clinical value, and patient benefits beyond basic insurance coverage [3] - The introduction of the commercial health insurance catalog is expected to clarify the boundaries of basic medical insurance and promote the differentiated development of commercial health insurance [3]